Clinical Trials Logo

Clinical Trial Summary

Respiratory diseases (asthma, cystic fibrosis, COPD…) need for the diagnosis and the follow-up the use of pulmonary function tests. These technics which are used since the nineteenth century and their discovery by Hutchinson, are now currently performed in pediatrics hospitals but they require trained personnel. Spirometry can be a difficult technic, especially for children. The accuracy and repeatability depend on many factors: equipment, patient effort, supervision and encouragement of a technician. A longitudinal follow up of measures can be good especially in pediatric populations, where children have generally more difficulties recognising their symptoms. Cystic fibrosis is a severe genetic chronic disease, that affects 1/4500 birth in France. It's a multi system disease that affects the respiratory system, with a decline in lung function over the time and consecutive to pulmonary exacerbations, the digestive system (malabsorption of fat and vitamins) and the endocrine system (diabetes). Pulmonary function is an important clinical indicator of the health of individuals with cystic fibrosis. Close monitoring of patient health with daily recording of physical measurements and symptoms didn't have a negative impact, home spirometry function test could help detect earlier a decline of the lung function and pulmonary exacerbations. Frequent exacerbations are associated with morbidity, mortality, accelerated decline in lung function and a decreased quality of life. They are also a major driver of health costs.Their early detection is a goal. Children with cystic fibrosis have more difficulties recognizing symptoms of exacerbations. Few studies in pediatric showed a good observance in realizing home spirometry, especially in young patients and those living far from the hospital and with a good satisfaction. Daily monitoring of lung function is probably too tedious for children who already have lots of medication. Medical adhesion of adolescent's patients is often suboptimal, compared with younger patients. But it's during this period that the decline of the respiratory function is the most important, with its principal cause: pulmonary exacerbations. Frequent home pulmonary function test is possible and can improve medication adherence without adding too much time, but there was no change in the decline of the FEV1 and the number of pulmonary exacerbations. The association of home monitoring of lung function and a symptom questionary (cough, sputum and dyspnea) can predict exacerbation with a good specificity and sensibility. The Mir Spirobank Smart is a bluetooth connected device, permitting patients to realize spirometry at home with a smartphone. The accuracy of the Spirobank Smart compared with a spirometry in a hospital showed a good correlation (asthma and COPD population), if it's used by trained personnel. The aim of this study is to determine the feasibility of a home respiratory monitoring in a pediatric cohort of patients with cystic fibrosis and the satisfaction of the kids, the parents and the team of the CRCM.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04837911
Study type Interventional
Source Central Hospital, Nancy, France
Contact Aurélie Mrs TATOPOULOS, Doctor
Phone 033383154556
Email au.tatopoulos@chru-nancy.fr
Status Not yet recruiting
Phase N/A
Start date April 1, 2021
Completion date April 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Active, not recruiting NCT04602468 - Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Phase 4
Completed NCT06109675 - Nutritional Status Assessment of Pediatric Cystic Fibrosis Patients and Effect of Nutrition Education on Nutritional Status N/A
Active, not recruiting NCT04392544 - Intestinal Inflammation in CF Patients
Completed NCT04084041 - Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis N/A
Not yet recruiting NCT03292718 - Clinical Trial to Assess Influence of MyCyFAPP Use on GI Related QOL in Children With Cystic Fibrosis N/A
Not yet recruiting NCT05493137 - Physical Activity Levels of Parents of Children With Cystic Fibrosis- (PHACTS-CF)
Enrolling by invitation NCT06188988 - Viral Infections and Airway Microbiome in Young Children With Cystic Fibrosis
Recruiting NCT04174664 - Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation
Completed NCT04138589 - Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function
Completed NCT03579173 - Determinants of Early Cystic Fibrosis Lung Disease
Recruiting NCT05850351 - Virtual Reality Based Tele-Exercises on Exercise Capacity in Cystic Fibrosis N/A
Completed NCT04463628 - Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic
Completed NCT04835376 - Percussion Palm Cup: Safety and Usability in Infants and Children With Cystic Fibrosis N/A
Completed NCT04293926 - Heart Rate Variability in Children and Adolescents With Cystic Fibrosis N/A
Completed NCT04987567 - Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients N/A
Withdrawn NCT04415268 - Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis N/A
Not yet recruiting NCT06066723 - 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Terminated NCT03939065 - Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management N/A
Active, not recruiting NCT04613128 - The PROMISE Pediatric Study 6 to 11 Years Old